The next generation of weight-loss drugs could be next year, and they could game-changing. The treatment, being "Ozempic 2.0," is a pill version of the already widely-used Ozempic. Novo Nordisk, the pharmaceutical company the new tablet form, said its initial clinical trials that Ozempic 2.0 " weight by an average of 10.5 per cent". Rival company Eli Lilly is also on a pill. Its executive vice president, Kenneth Custer, said: "We are with urgency toward global regulatory submissions to potentially the needs of patients." The drugs are currently approval from the Food and Drug Administration (FDA) in the USA.
The game-changing medicines could life much easier for those to shed weight, and for people with diabetes. Eli Lilly Chief Scientific Officer Dan Skovronsky said: "For the majority of patients, this could the main medicine that they to control their type 2 diabetes as well as their obesity." Currently, the drug is in the form of a once-weekly injection via an injectable pen. The pen has to be . Mr Custer told reporters: "If , we are ready to offer a convenient, once-daily pill that can be globally, removing barriers and redefining how obesity is around the world." It is also likely that the new treatment will cheaper.
